Rational design of next-generation PDK1 modulators: Addressing selectivity and resistance through molecular insights — A medicinal chemistry perspective
Bioorganic Chemistry · 2025
DOI: 10.1016/j.bioorg.2025.109239 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Bioorganic Chemistry, 2025. Verfasst von Yuxing Fu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Jiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy, Jiangxi Science & Technology Normal University, 605 Fenglin Road…. Hauptthemen laut MEDLINE: Drug Design, Protein Kinase Inhibitors, 3-Phosphoinositide-Dependent Protein Kinases, Pyruvate Dehydrogenase Acetyl-Transferring Kinase. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 109 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Jiangxi Provincial Natural Science Foundation, Jiangxi Science and Technology Normal University.
Abstract (Originalsprache)
3-Phosphoinositide-dependent protein kinase 1 (PDK1) serves as a critical signaling hub regulating cellular proliferation, metabolism, and survival. Its dysregulated activation is strongly linked to cancer, metabolic disorders, and neurodegenerative diseases, establishing small-molecule PDK1 modulators as a major research focus in medicinal chemistry. Early development focused on ATP-competitive inhibitors; however, their clinical utility was limited by off-target effects and suboptimal membrane permeability. Recent structure-based drug design approaches have yielded novel chemotypes. Nevertheless, PDK1 inhibitors face significant challenges, including insufficient selectivity, suboptimal drug-like properties, and emerging mechanisms of therapeutic resistance. This review provides a systematic overview of the development of PDK1 modulators, categorizing them into allosteric binders, ATP-competitive inhibitors, and agents inducing unique DFG-out conformations based on their mechanisms of action and binding modes. Notably, several natural products targeting PDK1 to modulate the PDK1/Akt/mTOR pathway have been identified. Their structural diversity offers valuable insights for the design of next-generation inhibitors with enhanced selectivity and reduced off-target toxicity. We comprehensively analyze the structure-activity relationships (SAR), biological activities, and mechanisms of action of these modulators, while also addressing persistent challenges and therapeutic opportunities in the field. This work offers rational design frameworks and strategic insights for developing novel PDK1-targeted therapeutics with optimized efficacy and safety profiles.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy, Jiangxi Science & Technology Normal University, 605 Fenglin Road, Nanchang, Jiangxi, 330013, China.
- Jiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy, Jiangxi Science & Technology Normal University, 605 Fenglin Road, Nanchang, Jiangxi, 330013, China. Electronic address: sunyijiangxi@q…
- Jiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy, Jiangxi Science & Technology Normal University, 605 Fenglin Road, Nanchang, Jiangxi, 330013, China. Electronic address: shanxu9891@126…
Förderung
- National Natural Science Foundation of China
- Jiangxi Provincial Natural Science Foundation
- Jiangxi Science and Technology Normal University
Zitieren
APA
Fu, Y., Zhu, Y., Zhou, X., Xiao, C., Zheng, P., Sun, Y., & Xu, S. (2025). Rational design of next-generation PDK1 modulators: Addressing selectivity and resistance through molecular insights — A medicinal chemistry perspective. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2025.109239
Vancouver
Fu Y, Zhu Y, Zhou X, Xiao C, Zheng P, Sun Y, et al. Rational design of next-generation PDK1 modulators: Addressing selectivity and resistance through molecular insights — A medicinal chemistry perspective. Bioorganic Chemistry. 2025. doi:10.1016/j.bioorg.2025.109239
BibTeX
@article{Fu2025,
author = {Fu, Yuxing and Zhu, Yuxuan and Zhou, Xin and Xiao, Chenxi and Zheng, Pengwu and Sun, Yi and Xu, Shan},
title = {Rational design of next-generation PDK1 modulators: Addressing selectivity and resistance through molecular insights — A medicinal chemistry perspective},
journal = {Bioorganic Chemistry},
year = {2025},
doi = {10.1016/j.bioorg.2025.109239}
}
EUVIMED